Toxicity and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan: Does Body Composition Matter?
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Purpose. This study aimed to evaluate the association between early changes in body composition and T-DXd treatment-related toxicity and outcomes. Patients and Methods. This retrospective multicentre observational study included 50 MBC patients treated with T-DXd at ASST Spedali Civili di Brescia and Sant’Anna Hospital of Como. Body composition parameters—skeletal muscle area (SMA), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and intramuscular adipose tissue (IMAT)—were assessed on CT scans at baseline and after 3 months (Δt0–t1). Toxicities were graded according to CTCAE v5.0. Associations between body composition changes, toxicity, progression-free survival (PFS), and overall survival (OS) were analyzed. Results Early changes in body composition were observed, with a significant increase in VAT (+ 15.3%, p = 0.05) and non-significant increases in SAT and IMAT, alongside a decline in SMA. Increased SAT (Δt0–t1), particularly above the median, was significantly associated with higher grades of fatigue (p = 0.02) and nausea (p = 0.04), while muscle loss showed a trend toward increased fatigue severity (p = 0.06). Increases in SAT and VAT were associated with worse OS (p < 0.01), and VAT increase was also associated with shorter PFS (p = 0.02). No association was found between body composition changes and dose reductions. Conclusion. Early alterations in body composition, particularly adipose tissue expansion, are associated with treatment-related toxicity and poorer outcomes in patients receiving T-DXd. These findings support longitudinal CT body composition assessment as a dynamic imaging biomarker of host response to therapy, providing prognostic information beyond conventional anthropometric measures.
Source: Research Square
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7204139013
